← Every company
CSL Ltd Patents
What CSL Ltd has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
CSLLY on carbonthat →Filings on file
52
Granted
5
Still pending
47
Filed under
15 names
52 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| METHOD OF PURIFICATIONFiled as CSL BEHRING AG2025-12-29Peter Dollinger | pending |
| Immunoglobulin preparations for treatment of systemic sclerosisC07K 16/06, A61P 37/06, A61K 9/0019, A61K2039/505, A61K2039/545, C07K 16/18, C07K2317/21Filed as CSL Behring AG2025-11-07Maria Gasior | pending |
| AUTONOMOUS AND RESILIENT INTEGRATED CIRCUIT DEVICEH04W 76/19, G08B 25/004, H04W 8/183, H04W 4/60, H04W 76/50, G08B 25/08, G08B 25/10, H04L 41/0809, H04M 11/04, H04W 48/18, H04W 88/06, H04W 88/08Filed as CSL (DualCom) Limited.2025-10-14Richard Benjamin Cunliffe | pending |
| OPTIMISED POLYNUCLEOTIDESFiled as CSL BEHRING LLC2025-08-13Florian AESCHIMANN | pending |
| METHOD FOR REDUCING PROTEASE ACTIVITY IN A SOLUTION COMPRISING ANTI-D IMMUNOGLOBULINC07K 16/4241, C07K 1/18, C07K 1/34, C07K 1/36Filed as CSL BEHRING AG2025-07-24Matthias Spiess | pending |
| HEMOPEXIN FORMULATIONSA61P 7/04, A61K 9/0019, A61K 9/08, A61K 38/16, Y02A 50/30, A61K 38/17, A61K 38/1709, A61K 47/02, A61K 47/12, A61K 47/26Filed as CSL Behring AG2025-07-14Thomas GENTINETTA | pending |
| TREATMENT OF MYOCARDITIS BY ADMINISTRATION OF ANTI-INTERLEUKIN-6 ANTIBODIESC07K 16/248, A61P 9/00, A61K 9/0019, A61K 45/06, A61K2039/505, A61K2039/54, A61K2039/545, C07K2317/52, C07K2317/565Filed as CSL Innovation Pty Ltd2025-06-20Padmapriya PONNUSWAMY | pending |
| FcRn Antagonists and Uses ThereofC07K 14/70535, C07K 14/765, C07K 16/283, A61P 37/06, A61K 38/00, A61K2039/505, C07K2317/52, C07K2317/76, C07K2317/92, C07K2319/30, C07K2319/31Filed as CSL Innovation PTY LTD2025-06-16Anne Verhagen | pending |
| METHODS OF TREATING OR PREVENTING A COMPLICATION OF SICKLE CELL DISEASEA61K 35/18, A61K 39/3955, C07K 16/243, C07K 16/2803, A61P 7/06, A61P 7/00, A61P 9/10, A61P 9/00, A61K2039/505, C07K 14/535, C07K 14/7153, C07K 16/2866, C07K2317/56, C07K2317/565, C07K2317/622, C07K2317/626, C07K2317/76Filed as CSL Innovation Pty Ltd2025-05-23Lisa Margareta LINDQVIST | pending |
| METHOD OF PURIFYING HEMOPEXIN USING MIXED-MODE CHROMATOGRAPHYC07K 1/18, C07K 14/47, A61K 38/00, A61K 38/1709, C07K 1/165, C07K 1/34, C07K 1/36, C07K 14/4717Filed as CSL Behring AG2025-05-15Karl Beaumont MCCANN | pending |
| TREATMENT OF CIDPC07K 16/06, A61P 25/02, A61B 5/395, A61B 5/294, A61B 5/388, A61B 5/4082, A61B 5/6824, A61B 5/6829, A61K2039/505Filed as CSL Behring AG2025-05-12Vera BRIL | pending |
| A SCREENING METHODC12N 15/1082, C12N 15/86, C12N 15/85, C12N 15/907, C12N2740/16043, C12N2740/16051, C12N2800/30, C12N2800/70, C12N2830/40, C12N2830/48, C12N2830/50Filed as CSL BEHRING LLC2025-05-01Florian AESCHIMANN | pending |
| CLAZAKIZUMAB FOR TREATMENT OF END-STAGE KIDNEY DISEASEFiled as CSL BEHRING LLC2025-04-25PIERLUIGI TRICOCI | pending |
| Method of Treating Severe AsthmaA61P 11/06, C07K 16/2866, A61K 9/0019, A61K 38/00, A61K2039/505, C07K 16/244, C07K 16/28, C07K2317/565, C07K2317/76, C07K2317/92Filed as CSL Innovation PTY LTD2025-04-18Steven Bozinovski | pending |
| FACTOR IX VARIANT POLYPEPTIDES FOR ADMINISTRATION TO SOFT TISSUEA61K 38/4846, C12N 9/644, A61P 7/04, C12Y 304/21022Filed as CSL Innovation Pty Ltd2025-04-09Steffi Knoll MACHADO | pending |
| METHODS OF REDUCING OR HINDERING DEVELOPMENT OF ISCHEMIA-REPERFUSION INJURY DUE TO KIDNEY TRANSPLANTATION WITH AN ANTIBODY THAT INHIBITS GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) SIGNALINGC07K 16/2866, A61P 9/10, A61P 13/12, A61K2039/505, A61K2039/545, C07K2317/21, C07K2317/34, C07K2317/76, A61P 43/00, A61K 39/3955, A61K2039/54, C07K 16/18Filed as CSL Limited2025-02-27Ingela VIKSTROM | pending |
| Haptoglobin for Use in Treating or Preventing Exaggerated Erectile Response or Erectile DysfunctionA61K 38/1709, A61K 38/1722, C07K 14/47, A61P 7/06, A61P 15/10, A61P 15/00, A61K 48/005, C12N 15/86, C12N2750/14143Filed as CSL Behring AG2025-02-27Fábio Henrique Da Silva | pending |
| AUTONOMOUS AND RESILIENT INTEGRATED CIRCUIT DEVICEH04W 76/19, G08B 25/004, H04W 8/183, H04W 4/60, H04W 76/50, G08B 25/08, G08B 25/10, H04L 41/0809, H04M 11/04, H04W 48/18, H04W 88/06, H04W 88/08Filed as CSL (DualCom) Limited2024-12-24Richard Benjamin Cunliffe | 12471169 |
| METHODS AND SYSTEMS FOR PLASMA PROCESSINGFiled as CSL PLASMA INC.2024-12-23Nathan BRINKMAN | pending |
| METHOD OF MONITORING PARAMETERS IN TURBID SOLUTIONSG01N 21/359, G01N 21/274, G01N 33/487, G01N2201/1293Filed as CSL BEHRING AG2024-12-23Michael BIERI | pending |
| IMPROVED MEDIA FOR THE EXPRESSION OF RECOMBINANT VITAMIN K-DEPENDENT PROTEINSC12N 9/6437, A61K 38/00, C07K 14/4702, C07K 14/745, C07K 14/76, C07K2319/31, C12N 5/0682, C12N 5/16, C12N2500/30, C12N2500/44Filed as CSL Behring Lengnau AG2024-12-17Yih Yean LEE | pending |
| PURIFICATION OF SOLUBLE COMPLEMENT RECEPTOR AND VARIANTS THEREOFC07K 1/20, B01D 15/327, B01D 15/361, B01D 15/362, B01D 15/363, C07K 1/18, C07K 14/705, C07K 14/70553, C07K 14/70596, C07K 14/723, C07K2319/21Filed as CSL Innovation Pty Ltd.2024-12-16Erik HINZE | pending |
| METHODS OF PRODUCING AN ENVELOPED VIRUSC12N 7/00, C12N 15/86, C12N 5/0018, C12N 5/0686, C12N 13/00, C12N2523/00, C12N2740/10043, C12N2740/10052, C12N2740/16051, C12N2740/16052, C12N2830/006Filed as CSL Behring LLC2024-12-13Holger LAUX | pending |
| METHOD OF FILTERING SOLIDS FROM A SOLUTION DERIVED FROM PLASMAA61M 1/3496, B01D 63/04, B01D 69/02, A61M 1/3692, B01D2311/2523, B01D2325/02834, B01D2325/02833, A61M2202/0415, A61M2205/3334, A61M2205/7554, B01D 61/14, B01D 63/02, B01D 65/02, B01D 65/08, B01D 69/08, B01D2311/14, B01D2311/16, B01D2311/165, B01D2311/18, B01D2315/10, B01D2315/20, B01D2321/04, B01D2321/12, B01D2321/168, B01D2325/02, C07K 1/34Filed as CSL BEHRING (AUSTRALIA) PTY LTD2024-11-26Karl MCCANN | pending |
| METHOD OF SEPARATING SOLIDS FROM A SOLUTION DERIVED FROM PLASMAA61K 35/16, B01D 21/262, B04B 1/20, B01D 21/26, B01D2221/10, B04B 13/00Filed as CSL BEHRING (AUSTRALIA) PTY LTD2024-11-25Karl MCCANN | pending |
| Pharmaceutical Product With Increased Stability Comprising ImmunoglobulinsA61K 39/395, A61K 39/39591, C07K 16/00, A61P 37/02, A61P 25/28, A61P 19/02, A61P 19/08, A61P 25/00, A61P 25/16, A61K2039/505, A61M 5/002, A61M 5/178, B65D 25/14, B65D 75/36, B65D 81/268, B65D 81/30, C07K 1/00, C07K2317/10, C07K2317/21, C07K2317/94, C09K 11/06Filed as CSL Behring AG2024-10-09Renzo PEDRUSSIO | pending |
| METHODS OF SANITIZING AND/OR REGENERATING A CHROMATOGRAPHY MEDIUMA61L 2/18, B01D 15/3809, B01J 49/05, B01J 49/07, B01J 49/53, B01J 49/50, B01J 49/06, B01J 49/57, A61L2101/02, A01P 1/00, B01D 15/1896, A01N 59/00, B01D 15/20, B01D 15/203, B01D 15/327, B01D 15/34, B01D 15/361, B01D 15/426, B01J 20/267, B01J 20/286, B01J 20/3425, B01J 20/3475, B01J 39/26, B01J 41/20, G01N 33/54386Filed as CSL BEHRING AG2024-10-08Peter DOLLINGER | pending |
| METHODS OF TREATING OR PREVENTING A CARDIOVASCULAR SYSTEM COMPLICATION OF SICKLE CELL DISEASE WITH AN ANTI-G-CSFR ANTIBODYA61K 35/18, A61K 39/3955, C07K 16/243, C07K 16/2803, A61P 7/06, A61P 7/00, A61P 9/10, A61P 9/00, A61K2039/505, C07K 14/535, C07K 14/7153, C07K 16/2866, C07K2317/56, C07K2317/565, C07K2317/622, C07K2317/626, C07K2317/76Filed as CSL Innovation Pty Ltd2024-10-08Lisa Margareta LINDQVIST | 12357689 |
| METHODS OF PREPARING ALBUMIN PREPARATIONSC07K 14/765, C07K 1/145, C07K 1/18Filed as CSL Behring LLC2024-10-03Charles Arnold | pending |
| METHODS OF PURIFYING AN ENVELOPED VIRUSC12N 7/00, B01D 15/1896, B01D 15/203, B01D 15/363, B01D 15/426, B01D 61/145, B01D2315/10, B01D2315/16, C12N 9/22, C12N 15/86, C12N2740/10021, C12N2740/10051, C12N2740/16043, C12N2740/16051, C12Y 301/30002Filed as CSL Behring LLC2024-09-27Tobias BRANDT | pending |
| APPARATUS AND METHOD FOR CLEANING FILTER PLATESB08B 3/022, B01D 41/04, B08B 3/024Filed as CSL Behring LLC2024-09-17Donald Wesley Gallagher | pending |
| Method of Treating an Eosinophil-Associated DiseaseC07K 16/2866, A61P 11/00, A61P 29/00, A61K2039/505, C07K2317/524, C07K2317/526, C07K2317/55, C07K2317/565, C07K2317/622, C07K2317/76, G01N 33/5094Filed as CSL Innovation Pty Ltd2024-09-12Steven Bozinovski | pending |
| Methods of Bone Marrow ConditioningC07K 16/2803, A61P 7/00, A61P 37/06, A61P 35/00, A61K 35/28, A61K2039/505, C07K2317/33, C07K2317/34, C07K2317/52, C07K2317/53, C07K2317/565, C07K2317/73, C07K2317/76, C07K2317/77, C07K2317/92Filed as CSL Innovation Pty Ltd2024-08-29Con Panousis | pending |
| HIGH-DENSITY VIRAL VECTOR FORMULATIONS AND USES THEREOFFiled as CSL Behring LLC2024-08-20Andreas GILLE | pending |
| LIGHTING DEVICE ASSEMBLY WITH DRIVER RAIL MOUNT SYSTEMF21V 21/02, F21V 29/70, F21V 15/01, F21V 17/164, F21V 23/007, F21Y2115/10, F21S 8/026Filed as Troy-CSL Lighting, Inc.2024-07-24Kenneth James Moore | 12416395 |
| LIGHTING DEVICE ASSEMBLY WITH ADJUSTMENT MECHANISMF21S 8/02, F21V 17/02, F21Y2115/10, F21S 8/022, F21S 8/024, F21S 8/026, F21S 8/028, F21V 14/02, F21V 14/04, F21V 14/06, F21V 14/08, F21V 15/01, F21V 17/005, F21V 17/104, F21V 17/162, F21V 17/164, F21V 19/0035, F21V 19/004, F21V 19/0045, F21V 19/02, F21V 21/04, F21V 21/041, F21V 21/042, F21V 21/043, F21V 21/044, F21V 21/045, F21V 21/046, F21V 21/047, F21V 21/048, F21V 21/049, F21V 21/088, F21V 21/14, F21V 21/22, F21V 21/34Filed as Troy-CSL Lighting, Inc.2024-07-24Kenneth James Moore | 12607328 |
| LIGHTING DEVICE ASSEMBLY WITH LIGHTING DEVICE ASSEMBLY WITH ADJUSTMENT MECHANISMF21V 29/70, F21V 15/01, F21Y2115/10, F21S 8/026, F21V 19/02, F21V 21/30, F21V 23/002, F21V 23/06Filed as Troy-CSL Lighting, Inc.2024-07-24Kenneth James Moore | pending |
| METHOD OF TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE LEUKEMIAC07K 16/2866, A61K 47/6867, A61K 47/642, A61K 31/122, A61K 31/4545, A61K 31/497, A61K 31/506, A61K 38/1793, A61K 38/193, A61K 38/202, A61K 39/3955, A61K 39/39558, A61K 45/06, C07K2317/24, C07K2317/52, C07K2317/732, A61P 43/00, A61P 35/02, A61K2300/00Filed as CSL LIMITED2024-07-17Devendra Keshaorao HIWASE | pending |
| ANTIBODIES AGAINST G-CSFR AND USES THEREOFC07K 16/2866, A61P 37/00, A61P 7/00, A61P 37/06, A61P 19/02, A61P 11/00, A61P 25/00, A61P 29/00, A61P 35/00, A61K2039/505, A61K2039/545, C07K2317/21, C07K2317/33, C07K2317/34, C07K2317/55, C07K2317/73, C07K2317/76, C07K2317/92Filed as CSL LIMITED2024-07-16Andrew Donald Nash | pending |
| METHODS OF PURIFYING AN ENVELOPED VIRUSFiled as CSL Behring LLC2024-07-12Tobias BRANDT | pending |
| LIGHTING DEVICE ASSEMBLY WITH HEAT SINKF21V 29/503, F21V 29/89, F21Y2115/10, F21S 8/026, F21V 19/02, F21V 21/047, F21V 21/30Filed as Troy-CSL Lighting, Inc.2024-06-26Joshua James Portinga | 12607339 |
| Methods of Enveloped Virus TransductionFiled as CSL Behring LLC2024-06-24Jarrod J. Kennedy | pending |
| PROTEIN FORMULATIONS AND USES THEREOFC07K 16/22, A61K 47/183, A61K 47/22, A61K 47/26, C07K2317/24, C07K2317/52, C07K2317/565, C07K2317/76Filed as CSL Innovation Pty Ltd2024-05-31Mouhamad RESLAN | pending |
| WISKOTT-ALDRICH SYNDROME BINDING PROTEINS AND USES THEREOFFiled as CSL Behring LLC2024-05-30Andrew Bruce HAMMET | pending |
| ANTIBODIES TO IL-6 FOR TREATMENT OF END-STAGE KIDNEY DISEASEFiled as CSL BEHRING LLC2024-04-29Pierluigi Tricoci | pending |
| CLAZAKIZUMAB FOR TREATMENT OF END-STAGE KIDNEY DISEASEFiled as CSL BEHRING LLC2024-04-29Pierluigi Tricoci | pending |
| CELL LINES OVEREXPRESSING VESICULAR STOMATITIS VIRUS GFiled as CSL Behring LLC2024-04-19Maximilian KLIMPEL | pending |
| METHODS OF PRODUCING AN ENVELOPED VIRUSFiled as CSL Behring LLC2024-04-19Maximilian KLIMPEL | pending |
| METHODS OF TREATING OR PREVENTING A COMPLICATION OF SICKLE CELL DISEASEFiled as CSL Innovation Pty Ltd2024-04-17Lisa Margareta Lindqvist | pending |
| Reconstituted HDL FormulationA61K 38/1709, A61K 9/0019, A61K 9/19, A61K 47/10, A61K 47/24, A61K 47/26, C07K 14/775Filed as CSL LIMITED2024-04-12Yvonne Vucica | pending |
| SOCIAL-GRAPH OVERLAY IN DATA EXCHANGESFiled as CSL Behring LLC2024-04-04Noelle Villa | pending |
| DATA SET DISCOVERY IN DATA EXCHANGESFiled as CSL Behring LLC2024-04-04Sterling Foster | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on CSLLY
Company overviewEverything on CSLLY in one place, with the price.Who owns itEvery manager reporting a position in CSLLY.LobbyingWhat CSLLY spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on CSLLY's account, and who they worked for.Federal contractsWhat federal agencies pay CSLLY.